- Home
- EVI vs EXEL Comparison
EVI vs EXEL Comparison
Compare EVI & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVI | EXEL |
|---|---|---|
| Founded | 1959 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.9M | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | EVI | EXEL |
|---|---|---|
| Price | $22.76 | $42.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 24 |
| Target Price | $40.00 | ★ $45.18 |
| AVG Volume (30 Days) | 16.0K | ★ 2.6M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | 0.39 | ★ 2.38 |
| Revenue | $404,474,000.00 | ★ $2,288,218,000.00 |
| Revenue This Year | $13.65 | $9.84 |
| Revenue Next Year | $4.49 | $11.92 |
| P/E Ratio | $57.36 | ★ $17.67 |
| Revenue Growth | ★ 12.63 | 9.93 |
| 52 Week Low | $14.99 | $31.90 |
| 52 Week High | $34.82 | $49.62 |
Technical Indicators
Market Signals| Indicator | EVI | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 54.09 |
| Support Level | $22.20 | $40.83 |
| Resistance Level | $23.56 | $42.09 |
| Average True Range (ATR) | 1.20 | 1.09 |
| MACD | 0.51 | -0.22 |
| Stochastic Oscillator | 86.21 | 47.70 |
Price Performance
Historical ComparisonAbout EVI EVI Industries Inc.
EVI Industries Inc through its subsidiaries, is a distributor that sells, leases, and rents commercial, industrial, and vended laundry and dry cleaning equipment and steam and hot water boilers manufactured by others, supplies related replacement parts and accessories, designs and plans turn-key laundry, dry cleaning, and boiler systems, and provides installation and maintenance services to its customers, which include commercial, industrial, institutional, government, and retail customers. These activities are conducted in the United States, Canada, the Caribbean, and Latin America.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.